United Therapeutics Corporation (NASDAQ:UTHR) Q3 2021 Earnings Conference Call November 3, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Joseph Thome - Cowen and Company Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer Eun Yang - Jefferies Operator Good morning and welcome to the United Therapeutics Corporati ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Jurisdiction of (I.R.S. Employ ...

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2021 Earnings Conference Call August 4, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President, Product Development Conference Call Participants Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer & Company Joseph Thome - Cowen & ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 0-26301 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.01 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2021 Earnings Conference Call May 5, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Eun Yang - Jefferies Liana Moussatos - Wedbush Securities Hartaj Singh - Oppenheimer & Company Joe Thome - Cowen & Company Operator Good morning, and welcome to the United Therape ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2020 Earnings Conference Call February 24, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Leigh Peterson - VP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Joseph Thome - Cowen and Company Liana Moussatos - Wedbush Eun Yang - Jefferies Jessica Fye - JPMorgan Martin Auster - Credit Suisse Hartaj Singh - Oppenheimer Terence Flynn - G ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (S ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2020 Earnings Conference Call October 28, 2020 9:00 AM ET Corporate Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairman & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer Leigh Peterson - Vice President, Product Development James Edgemond - Chief Financial Officer & Treasurer Conference Call Participants Hartaj Singh - Oppenheimer Eun Yang - Jefferies Martin Auster - Credit Suisse Joseph Thome - C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1 ...